DE69027123D1 - Proliferative wirkung des leukämie-hemmungsfaktors auf satellitzellen - Google Patents

Proliferative wirkung des leukämie-hemmungsfaktors auf satellitzellen

Info

Publication number
DE69027123D1
DE69027123D1 DE69027123T DE69027123T DE69027123D1 DE 69027123 D1 DE69027123 D1 DE 69027123D1 DE 69027123 T DE69027123 T DE 69027123T DE 69027123 T DE69027123 T DE 69027123T DE 69027123 D1 DE69027123 D1 DE 69027123D1
Authority
DE
Germany
Prior art keywords
satellite cells
pct
cytokines
lif
alone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69027123T
Other languages
English (en)
Other versions
DE69027123T2 (de
Inventor
Lawrence Austin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University filed Critical Monash University
Publication of DE69027123D1 publication Critical patent/DE69027123D1/de
Application granted granted Critical
Publication of DE69027123T2 publication Critical patent/DE69027123T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
DE69027123T 1989-11-24 1990-11-20 Proliferative wirkung des leukämie-hemmungsfaktors auf satellitzellen Expired - Fee Related DE69027123T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ755289 1989-11-24
PCT/AU1990/000556 WO1991007992A1 (en) 1989-11-24 1990-11-20 Proliferative action of leukaemia inhibitory factor on satellite cells

Publications (2)

Publication Number Publication Date
DE69027123D1 true DE69027123D1 (de) 1996-06-27
DE69027123T2 DE69027123T2 (de) 1997-04-24

Family

ID=3774381

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69027123T Expired - Fee Related DE69027123T2 (de) 1989-11-24 1990-11-20 Proliferative wirkung des leukämie-hemmungsfaktors auf satellitzellen

Country Status (10)

Country Link
US (1) US5435999A (de)
EP (1) EP0502081B1 (de)
JP (2) JP3040815B2 (de)
AT (1) ATE138267T1 (de)
AU (1) AU624284B2 (de)
CA (1) CA2045630A1 (de)
DE (1) DE69027123T2 (de)
HK (1) HK1003475A1 (de)
NO (1) NO922008L (de)
WO (1) WO1991007992A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
ATE138268T1 (de) * 1990-03-20 1996-06-15 Amrad Corp Ltd Verfahren zur steuerung der neuronentwicklung und des neuronunterhalts
ATE199498T1 (de) * 1991-12-24 2001-03-15 Amrad Corp Ltd Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen
WO1994021272A1 (en) * 1993-03-17 1994-09-29 Amrad Corporation Limited A method for treating microbial infection in an animal by administering a composition comprising lif and a cytokine
US20020164313A1 (en) * 1995-03-16 2002-11-07 Tremblay Jacques P. Compositions comprising preconditioned myoblasts having enhanced fusion properties
US5833978A (en) * 1995-03-16 1998-11-10 Universite Laval Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of recessive myopathies like muscular dystrophy, for improving transplantation success
GB2301114A (en) * 1995-05-24 1996-11-27 Bradley Michael John Stringer Method for controlling differentiation of precursor cells
DE69637669D1 (de) * 1995-06-06 2008-10-16 Osiris Therapeutics Inc Myogene differenzierung menschlicher mesenchymaler stammzellen
DE69737460T2 (de) * 1996-10-18 2008-04-10 UNIVERSITé LAVAL Verfahren zur in-vitro-vorbehandlung von myoblasten in der transplantation
US20010041342A1 (en) * 1998-04-01 2001-11-15 The General Hospital Corporation, A Massachusetts Corporation Molecular marker for muscle stem cells
US7115417B1 (en) 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
AU2001251599B2 (en) 2000-04-14 2006-03-02 University Of Pittsburgh Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
CA2438904C (en) 2001-02-23 2012-09-04 The University Of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
CN103230415B (zh) 2003-04-25 2016-05-04 匹兹堡大学联邦制高等教育 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc）
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
GB2433122B (en) 2005-12-10 2008-07-23 Endet Ltd Gas sampling probe
US8105834B2 (en) 2007-01-11 2012-01-31 University of Pittsburgh—of the Commonwealth System of Higher Education Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using same
AU2009282619B2 (en) 2008-08-18 2015-08-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US9139814B2 (en) * 2008-09-22 2015-09-22 Universite Laval Culture medium for myoblasts, precursors thereof and derivatives thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87133B (pt) * 1987-04-02 1992-07-31 Amrad Corp Ltd Metodo de purificacao do factor inibidor da leucemia (lif) e de composicoes farmaceuticas contendo polipeptidos com actividade do lif
AU609128B2 (en) * 1987-04-02 1991-04-26 Amrad Operations Pty. Limited Leukaemia-inhibitory factor
EP0380646B1 (de) * 1988-08-04 1999-01-20 Amrad Corporation Limited (in vitro)-vermehrung von embryonalen stammzellen unter verwendung von leukämie-inhibitionsfaktor (lif)
WO1990002183A1 (en) * 1988-08-18 1990-03-08 Genetics Institute, Inc. Production of a novel lymphokine exhibiting differentiation inhibitory activity

Also Published As

Publication number Publication date
NO922008L (no) 1992-07-20
US5435999A (en) 1995-07-25
AU6896791A (en) 1991-06-26
JPH05502224A (ja) 1993-04-22
EP0502081A1 (de) 1992-09-09
JP2000128791A (ja) 2000-05-09
WO1991007992A1 (en) 1991-06-13
EP0502081A4 (en) 1993-05-05
AU624284B2 (en) 1992-06-04
CA2045630A1 (en) 1991-05-25
JP3040815B2 (ja) 2000-05-15
ATE138267T1 (de) 1996-06-15
DE69027123T2 (de) 1997-04-24
EP0502081B1 (de) 1996-05-22
NO922008D0 (no) 1992-05-21
HK1003475A1 (en) 1998-10-30

Similar Documents

Publication Publication Date Title
DE69027123D1 (de) Proliferative wirkung des leukämie-hemmungsfaktors auf satellitzellen
Felix et al. Bone-resorbing cytokines enhance release of macrophage colony-stimulating activity by the osteoblastic cell MC3T3-E1
ES2001967A6 (es) Un metoo para producir una proteina a partir de un cultivo de celulas.
DE3363781D1 (en) Homogeneous human-interleukin-2 and process for its preparation
DE69527540D1 (de) Verwendung von stammzellenfaktor und löslichen interleukin-6-rezeptor zur vermehrung der hämatopoietischen vorläuferzellen
NZ314644A (en) Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
CS407691A3 (en) Polypeptide, dna with a sequence encoding said polypeptide and said polypeptide use
EP0453453A4 (en) Leukaemia inhibitory factor from livestock species and use thereof to enhance implantation and development of embryonic cells
GR3022321T3 (en) Use of il-4 to treat solid tumors
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
AU5283890A (en) Fibroblast growth factor (fgf)-based stabilized compositions
PT100651A (pt) Muteinas da interleucina 6 (il-6) isentas de cisteina
DE69129113T2 (de) Stimulierung der stroma- und vorläuferzellen im knochenmark
US6423681B1 (en) Method of inducing formation of kidney epithelia from mesenchymal precursors
Sauder et al. Stimulation of muscle protein degradation by murine and human epidermal cytokines: relationship to thermal injury
CA2017315A1 (en) Interleukin i inhibitor
AU4299696A (en) Use of the hepatocyte growth factor to induce proliferation and differentiation of hemopoietic cells
HU210882A9 (en) Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
DE3879575T2 (de) Alpha-Carotin zur Wachstumshemmung von Krebszellen.
Austin Proliferative action of leukaemia inhibitory factor on satellite cells
Chao et al. Indirect inhibition of generation of murine lymphokine-activated killer cell activity in splenocyte cultures by interferon-gamma.
EP0620736A4 (en) A method for the treatment of tumours and sarcomas.
Wu et al. Effect of stem cell factor (c‐kit ligand) on clonogenic leukemic precursor cells: Synergy with other hematopoietic growth factors
Diezel et al. The effect of splenopentin (DA SP-5) on in vitro myelopoiesis and on AZT-induced bone marrow toxicity
Okigaki et al. Growth of human cervical epithelial cells in vitro

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee